Verastem Oncology, Inc. (NASDAQ: VSTM) is a biopharmaceutical company headquartered in Needham, Massachusetts.  We are developing a portfolio of novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth.

Verastem is a member of NASDAQ Biotechnology Index.

Investor Kit

Media kit Verastem Oncology

Investor Contact

John Doyle

Investor Relations
(781) 292-4279
info@verastem.com

Joe Rayne

Argot Partners
(617) 340-6075
joseph@argotpartners.com